Literature DB >> 21836608

C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells.

Y Satoh1, I Matsumura, H Tanaka, H Harada, Y Harada, K Matsui, M Shibata, M Mizuki, Y Kanakura.   

Abstract

Loss-of-function mutations of RUNX1 have been found in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDSs). Although several reports have suggested roles for RUNX1 as a tumor suppressor, its precise function remains unknown. Because gene alterations of RUNX1 by themselves do not lead to the development of leukemia in mouse models, additional mutation(s) would be required for leukemia development. Here, we report that the C-terminal deletion mutant of RUNX1, RUNX1dC, attenuates DNA-damage repair responses in hematopoietic stem/progenitor cells. γH2AX foci, which indicate the presence of DNA double-strand breaks, were more abundantly accumulated in RUNX1dC-transduced lineage(-)Sca1(+)c-kit(+) (LSK) cells than in mock-transduced LSK cells both in a steady state and after γ-ray treatment. Expression profiling by real-time -PCR array revealed RUNX1dC represses the expression of Gadd45a, a sensor of DNA stress. Furthermore, bone marrow cells from MDS/AML patients harboring the RUNX1-C-terminal mutation showed significantly lower levels of GADD45A expression compared with those from MDS/AML patients with wild-type RUNX1. As for this mechanism, we found that RUNX1 directly regulates the transcription of GADD45A and that RUNX1 and p53 synergistically activate the GADD45A transcription. Together, these results suggest Gadd45a dysfunction due to RUNX1 mutations can cause additional mutation(s) required for multi-step leukemogenesis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21836608     DOI: 10.1038/leu.2011.202

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  19 in total

1.  Guest editorial: introduction of Progress in Hematology in this issue.

Authors:  Yasushi Miyazaki
Journal:  Int J Hematol       Date:  2012-01-11       Impact factor: 2.490

2.  Association between Fas/FasL polymorphism and susceptibility to leukemia: a meta-analysis.

Authors:  Yiran Chen; Yiho He; Xiaotong Lu; Zhirui Zeng; Chen Tang; Tongyuan Xue; Yuhua Li
Journal:  Int J Clin Exp Med       Date:  2015-03-15

Review 3.  Molecular pathophysiology of myelodysplastic syndromes.

Authors:  R Coleman Lindsley; Benjamin L Ebert
Journal:  Annu Rev Pathol       Date:  2012-08-28       Impact factor: 23.472

Review 4.  The RUNX family: developmental regulators in cancer.

Authors:  Yoshiaki Ito; Suk-Chul Bae; Linda Shyue Huey Chuang
Journal:  Nat Rev Cancer       Date:  2015-01-16       Impact factor: 60.716

5.  Gadd45 in Normal Hematopoiesis and Leukemia.

Authors:  Dan A Liebermann
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 6.  Myeloid neoplasms and clonal hematopoiesis from the RUNX1 perspective.

Authors:  Yoshihiro Hayashi; Yuka Harada; Hironori Harada
Journal:  Leukemia       Date:  2022-03-30       Impact factor: 11.528

7.  Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia.

Authors:  Iléana Antony-Debré; Vladimir T Manchev; Nathalie Balayn; Dominique Bluteau; Cécile Tomowiak; Céline Legrand; Thierry Langlois; Olivia Bawa; Lucie Tosca; Gérard Tachdjian; Bruno Leheup; Najet Debili; Isabelle Plo; Jason A Mills; Deborah L French; Mitchell J Weiss; Eric Solary; Remi Favier; William Vainchenker; Hana Raslova
Journal:  Blood       Date:  2014-12-09       Impact factor: 22.113

8.  Helicase-like transcription factor is a RUNX1 target whose downregulation promotes genomic instability and correlates with complex cytogenetic features in acute myeloid leukemia.

Authors:  Chi Keung Cheng; Natalie P H Chan; Thomas S K Wan; Lai Ying Lam; Coty H Y Cheung; Terry H Y Wong; Rosalina K L Ip; Raymond S M Wong; Margaret H L Ng
Journal:  Haematologica       Date:  2016-01-22       Impact factor: 9.941

9.  [RUNX1 gene mutations are associated with adverse prognosis of patients with acute myeloidleukemia].

Authors:  Yanli Yang; Tiantian Li; Yinghua Geng; Jun Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2020-11-30

10.  Molecular biology of Philadelphia-negative myeloproliferative neoplasms.

Authors:  Paulo Vidal Campregher; Fábio Pires de Souza Santos; Guilherme Fleury Perini; Nelson Hamerschlak
Journal:  Rev Bras Hematol Hemoter       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.